Mechanical Circulatory Support Korea Post Market Surveillance Study (PMS)
Launched by MEDTRONIC CARDIAC RHYTHM AND HEART FAILURE · Sep 3, 2020
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The MCS Korea PMS is an observational study conducted at two sites. This MCS Korea PMS is required by the Ministry of Food and Drug Safety (MFDS) as a condition of product approval according to Regulation on Medical Device Re-examination. The designated re-examination period is seven years after the approval date (06 Dec 2013 \~ 05 Dec 2020). All patients who require treatment of a commercially available HVAD System for approved indications between the designated re-examination period at a participating PSR site are eligible for enrollment. All enrolled patients will be followed until patie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
- • Patient has or is intended to receive or be treated with an eligible product
- • Patient is consented within the enrollment window or waiver of consent is approved
- Exclusion Criteria:
- • Patient who is, or is expected to be inaccessible for follow-up
- • Patient with exclusion criteria required by local law
- • Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results (i.e. no required intervention that could affect interpretation of all-around product safety and or effectiveness)
About Medtronic Cardiac Rhythm And Heart Failure
Medtronic Cardiac Rhythm and Heart Failure is a leading division of Medtronic, dedicated to advancing innovative therapies for patients with cardiac rhythm disorders and heart failure. With a commitment to improving patient outcomes, this division focuses on developing cutting-edge medical devices and solutions that enhance the management of arrhythmias and heart failure. Leveraging extensive research and clinical expertise, Medtronic Cardiac Rhythm and Heart Failure aims to transform patient care through evidence-based approaches and a robust pipeline of groundbreaking technologies. Their work not only addresses immediate clinical challenges but also contributes to the long-term health and well-being of individuals with complex cardiac conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials